Form 4: Century Therapeutics CSO Sells Shares for Tax Obligations

Century Therapeutics' Chief Scientific Officer, Chad Cowan, disposed of 1,611 common shares to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Chad Cowan, Chief Scientific Officer of Century Therapeutics, Inc. (IPSC), reported a change in beneficial ownership.
• On January 2, 2026, 1,611 shares of common stock were disposed of at a price of $0.995 per share.
• This disposition was a routine transaction (Code 'F') representing shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units.
• The transaction was made pursuant to a Rule 10b5-1(c) pre-arranged plan.
• Following the transaction, Chad Cowan directly beneficially owns 1,043,476 shares of common stock.
• Additionally, 10,697 shares are indirectly held by the Cowan Investment Nominee Trust, for which the reporting person disclaims beneficial ownership except to the extent of any pecuniary interest.

Sentiment

Score: 5

Explanation: Neutral, as it's a routine tax-related transaction by an insider, not indicative of a change in sentiment towards the company's prospects or operational performance.

Future Outlook

NA

Industry Context

This is a routine insider transaction related to executive compensation and tax obligations, which is common across all industries for publicly traded companies. It does not provide specific insights into broader industry trends or competitive landscape.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine tax-related disposition of a small portion of an executive's holdings.
• No direct impact on employees, customers, suppliers, or creditors.

Key Dates

Recommendation

The transaction is a routine disposition of shares by an executive to cover tax obligations upon the vesting of restricted stock units. It does not reflect a change in the executive's confidence in the company or its future prospects, nor does it indicate any fundamental shift in the company's operations or financial health. Therefore, it does not provide a basis for altering an existing investment thesis.

Keywords

Century Therapeutics, IPSC, Chad Cowan, Form 4, Insider Transaction, Stock Sale, Tax Withholding, Restricted Stock Units, CSO